EQUITY RESEARCH MEMO

Biodeal Pharmaceuticals

Generated 5/24/2026

Executive Summary

Conviction (model self-assessment)65/100

Biodeal Pharmaceuticals is an Indian WHO-GMP certified CDMO specializing in small-molecule finished dosage forms, nasal sprays, nutraceuticals, and herbal products. Founded in 2007 and headquartered in Ahmedabad, the company leverages advanced formulation expertise and regulatory approvals (PIC/S, WHO-GMP) to serve domestic and international pharma brands. With 200-500 employees, it offers end-to-end manufacturing services, positioning itself as a key player in the growing contract manufacturing space, particularly in nasal drug delivery and nutraceuticals. The company's focus on high-demand segments and regulatory compliance provides a stable revenue base, though its private status limits visibility into financials.

Upcoming Catalysts (preview)

  • Q2 2027Expansion of Nasal Spray Manufacturing Capacity70% success
  • Q4 2026New PIC/S Certification for Additional Facility80% success
  • Q3 2026Strategic Partnership with Global Pharma Brand for Herbal Products60% success
Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)